Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 64
Selected: 0
NCT IDTitle
NCT04233021Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation
NCT02716311Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer
NCT00198380Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature
NCT00410683Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery
NCT07420439Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT01102231Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
NCT06656598Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
NCT00198406A FRENCH SURVEY OF THE DIAGNOSTIC AND THERAPEUTIC MANAGEMENT OF ELDERLY PEOPLE WITH HISTOLOGICALLY/CYTOLOGICALLY CONFIRMED LUNG CANCER.
NCT05273047RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC
NCT02784171Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
NCT03977194Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy
NCT01296113Chemotherapy for Lung Cancer in HIV-positive Patients
NCT02716272Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
NCT01700582French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings
NCT02273375Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT04775095BRAF V600-mutated Lung Carcinoma Treated With the Combination of Dabrafenib-trametinib: a Retrospective Evaluation
NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
NCT03030131Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer
NCT00930891Bevacizumab in Extensive Small Cell Lung Cancer
NCT00384826Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma
NCT04397575The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients
NCT03727477Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib
NCT00298415Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)
NCT02727335Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements
NCT05255302De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction
NCT02473133Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC
NCT00198432Chemoradiotherapy of NSCLC Stage IIIB
NCT04621188Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)
NCT04111705Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
NCT03304093Immunotherapy by Nivolumab for HIV+ Patients
NCT00433563Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer
NCT06053099A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)
NCT04920981Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC
NCT01631136Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer
NCT03591731Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
NCT00651456Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
NCT00198354Stage I/II NSCLC Perioperative Chemotherapy
NCT00535275NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy
NCT01763671Paclitaxel-bevacizumab in Advanced Lung Cancer
NCT03059667Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
NCT00198393Randomized Phase 2 Study of 3 Therapeutic Modalities in PS 2/3 Patients With NSCLC Stage IIIB/IV
NCT07234058Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
NCT05781308Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
NCT03845270Her2-positive Lung Cancer Treated With Dedicated Drug
NCT02046733Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
NCT04108026Immunotherapy in Patient With Poor General Condition
NCT05856695Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)
NCT04526782ENCOrafenib With Binimetinib in bRAF NSCLC
NCT03469960Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr
NCT01850303Maintenance After Induction Chemotherapy in Elderly Patients With Advanced Non-small Cell Lung Cancer